Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: SVB Securities Global Biopharma Conference on Thursday, February 16, 2023. Fireside Chat at 12:00 p.m. ET. 43rd Annual Cowen Healthcare Conference on Wed